Articles From: Almaden Website Service Interruption to Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results and Highlights Recent Period Activities


2014/3/24
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0935237001&sourceType=1 http://media3.marketwire.com/logos/20130124-almalogful.jpg VANCOUVER, BRITISH COLUMBIA --
Sign-up for Almaden Website Service Interruption investment picks
2014/1/21
Revlon, Inc. (NYSE:REV) announced today that Carrie Underwood is joining Almay as a Global Brand Ambassador.
Sign-up for Almay Names Carrie Underwood as a Global Brand Ambassador investment picks
2014/3/11
By Jim Jelter, MarketWatch SAN FRANCISCO (MarketWatch) -- While most of the nation was digging out this winter, California's great calamity has been relentless sunshine.
Sign-up for Almond crunch: California drought withers world supply investment picks
2014/3/14
Will Continue to Seek VN and PC Acquisition Opportunities LOUISVILLE, Ky.
Sign-up for Almost Family Announces Agreement to Acquire Caldwell County Hospital Home Health Agency investment picks
Acquires Controlling Interest in Imperium Health Management, LLC LOUISVILLE, Ky.
Sign-up for Almost Family Announces Strategic Investment in Accountable Care Organization Enablement Company investment picks
2014/3/11
LOUISVILLE, Ky.
Sign-up for Almost Family Reports Fourth Quarter and Full Year 2013 Results investment picks
LOUISVILLE, Ky.
Sign-up for Almost Family Reports Second Quarter 2013 Results investment picks
2013/11/5
In a separate release today, Almost Family announced an agreement to acquire SunCrest HealthCare.
Sign-up for Almost Family Reports Third Quarter 2013 Results investment picks
2014/1/14
LOUISVILLE, Ky.
Sign-up for Almost Family to Present at the 32nd Annual J.P. Morgan Healthcare Conference investment picks
2013/12/9
Major acquisition is largest in Company history Also appoints Daniel Schwartz SVP and Chief Operating Officer LOUISVILLE, Ky.
Sign-up for Almost Family, Inc. Completes Acquisition of SunCrest HealthCare investment picks
2013/11/5
Major acquisition is largest in Company history In a separate release today, Almost Family reported its third quarter 2013 results.
Sign-up for Almost Family, Inc. Signs Definitive Agreement to Acquire SunCrest HealthCare investment picks
2014/3/10
LOUISVILLE, Ky., March 10, 2014 (GLOBE NEWSWIRE) -- Almost Family, Inc. (Nasdaq:AFAM) , a leading regional provider of home health nursing and personal care services, announced today that it will report financial results for its fourth quarter and full year ended December 31, 2013 on Tuesday, March 11, 2014, publishing an earnings release before the market opens.
Sign-up for Almost Family, Inc. to Report Fourth Quarter and Full Year 2013 Financial Results on March 11, 2014 investment picks
2013/11/4
LOUISVILLE, Ky.
Sign-up for Almost Family, Inc. to Report Third Quarter 2013 Financial Results on November 5, 2013 investment picks
Almost Half of Homeowners Aren't Confident They Will Retire Debt-Free, Manulife Bank of Canada Survey Shows Canada NewsWire   WATERLOO, ON, Nov.
Sign-up for Almost Half of Homeowners Aren't Confident They Will Retire Debt-Free, Manulife Bank of Canada Survey Shows investment picks
2013/11/19
Fewer than half of homeowners are happy with how they've managed their debt in the past year.
Sign-up for Almost Half of Homeowners Aren't Confident They Will Retire Debt-Free, Manulife Bank of Canada Survey Shows investment picks
2013/12/5
ATLANTA, Dec.
Sign-up for Almost Two Million Account Passwords Stolen and Posted Online investment picks
2013/12/20
Alnylam Pharmaceuticals, Inc .
Sign-up for Alnylam and Collaborators Publish Novel Method for Detection of Tissue-Specific, RNAi-Mediated Gene Silencing investment picks
2014/3/6
Alnylam Pharmaceuticals, Inc .
Sign-up for Alnylam Announces Closing of Previously Announced Acquisition of Merck’s Sirna Therapeutics Subsidiary investment picks
2013/9/30
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it has completed enrollment in its Phase II trial with ALN-TTR02, an RNAi therapeutic targeting the transthyretin (TTR) gene for the treatment of TTR-mediated amyloidosis (ATTR). Recent interim results from this Phase II study showed that ALN-TTR02 achieved up to 93% knockdown of TTR – the disease-causing protein in ATTR.
Sign-up for Alnylam Completes Enrollment of Phase II Clinical Trial and Initiates Open-Label Extension (OLE) Study with ALN-TTR02, an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of Transthyretin-Mediated Amyloidosis (ATTR) investment picks
2014/1/22
Alnylam Pharmaceuticals , Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has initiated a Phase 1 study with ALN-AT3, a subcutaneously administered RNAi therapeutic targeting antithrombin (AT) for the treatment of hemophilia and rare bleeding disorders (RBD). ALN-AT3 has demonstrated efficacy in animal models of hemophilia, including in non-human primate models of induced hemophilia.
Sign-up for Alnylam Initiates Phase 1 Clinical Trial with ALN-AT3, a Subcutaneously Administered RNAi Therapeutic Targeting Antithrombin (AT) in Development for the Treatment of Hemophilia and Rare Bleeding Disorders (RBD) investment picks
2013/12/16
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has initiated a pilot Phase II study with ALN-TTRsc, a subcutaneously delivered RNAi therapeutic targeting the transthyretin (TTR) gene in development for the treatment of TTR-mediated amyloidosis (ATTR). The Phase II trial, which is now open for enrollment, is aimed at evaluating the tolerability and preliminary clinical activity of ALN-TTRsc in TTR cardiac amyloidosis patients with familial amyloidotic cardiomyopathy (FAC) – which is caused by autosomal dominant mutations in the TTR gene, or senile systemic amyloidosis (SSA) – which is caused by idiopathic accumulation of wild-type TTR in the heart.
Sign-up for Alnylam Initiates Phase II Clinical Trial with ALN-TTRsc, a Subcutaneously Delivered RNAi Therapeutic Targeting Transthyretin (TTR) in Development for the Treatment of TTR-Mediated Amyloidosis (ATTR) investment picks
2014/1/12
Alnylam Pharmaceuticals Inc. (ALNY), which develops therapies based on RNA interference, said it will buy Merck & Co.'s (MRK) subsidiary, Sirna Therapeutics Inc., which is also focused on RNAi.
Sign-up for Alnylam Pharmaceuticals Buys Merck's Sirna Therapeutics investment picks
2014/2/13
Alnylam Pharmaceuticals, Inc .
Sign-up for Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results and Highlights Recent Period Activities investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Almaden Website Service Interruption to Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results and Highlights Recent Period Activities
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity